|
ELF4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.4901999986009E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.09270000007101E-08 |
| Normal-vs-Stage2 |
8.233600E-02 |
| Normal-vs-Stage3 |
4.43880000000618E-06 |
| Normal-vs-Stage4 |
1.67480000001774E-06 |
| Stage1-vs-Stage2 |
2.361300E-03 |
| Stage1-vs-Stage3 |
6.994200E-01 |
| Stage1-vs-Stage4 |
4.308800E-01 |
| Stage2-vs-Stage3 |
6.602700E-03 |
| Stage2-vs-Stage4 |
1.678700E-03 |
| Stage3-vs-Stage4 |
7.126000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.10410003151662E-09 |
| Normal-vs-AfricanAmerican |
1.112370E-02 |
| Normal-vs-Asian |
4.89280000004477E-06 |
| Caucasian-vs-AfricanAmerican |
3.560600E-01 |
| Caucasian-vs-Asian |
8.820000E-01 |
| AfricanAmerican-vs-Asian |
5.271800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.29090000003485E-06 |
| Normal-vs-Female |
1.21000000019578E-07 |
| Male-vs-Female |
3.371600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.45659999617465E-08 |
| Normal-vs-Age(41-60Yrs) |
1.7853699999959E-05 |
| Normal-vs-Age(61-80Yrs) |
2.168600E-04 |
| Normal-vs-Age(81-100Yrs) |
2.944000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.714000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.903600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.644400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.735800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.917840E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.287400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.862200E-01 |
| Classical-VS-Follicular |
1.62447832963153E-12 |
| Classical-VS-Other |
1.193410E-01 |
| Classical-VS-Normal |
1.35500499709451E-11 |
| Tall-VS-Follicular |
3.95560000310269E-08 |
| Tall-VS-Other |
8.616500E-02 |
| Tall-VS-Normal |
1.26639999997735E-06 |
| Follicular-VS-Other |
4.139600E-02 |
| Follicular-VS-Normal |
6.724600E-01 |
| Other-VS-Normal |
2.145800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.220400E-04 |
| Normal-vs-N1 |
3.58190000004921E-06 |
| N0-vs-N1 |
2.554200E-02 |
|
|
